BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

...SVP of chemistry and biology business unit at Shanghai Medicilon Inc. (Shanghai:688202).Neuroscience and immuno-oncology company BioXcel...
...VP of R&D. BC Staff Intercept Blood System for plasma (amotosalen, Intercept Plasma System (S-59)) TScan Therapeutics Insilico Biotechnology Kira Biotech BioXcel Re-Vana...
BioCentury | Jun 26, 2020
Management Tracks

Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst

...Randy Scott to the board. Scott was executive chairman and CEO of Invitae Corp. (NYSE:NVTA). BioXcel...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...OTCQX:RHHBY), where she was global head of the pharma’s neuromuscular franchise. Neuroscience and immuno-oncology play BioXcel...
...VP of clinical development at Merus N.V. (NASDAQ:MRUS). Robin Sawka, BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise Therapeutics BioXcel...
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...Inc. Dewpoint Therapeutics FerGene Inc. Adverum Biotechnologies Inc. Epsilen Bio s.r.l. Kaleido Biosciences Inc. Laboratory for Advanced Medicine Inc. Mundipharma International Ltd. MacroGenics Inc. BioXcel...
BioCentury | Jan 18, 2019
Financial News

Gore Range closes its inaugural fund

...Fund I raised. Fund I has made 13 investments, including in neuroscience and immuno-oncology company BioXcel...
...dermatology, cancer and cardiovascular biotechs and innovative technology companies. Gore Range Capital, New York, N.Y. Jennie Walters BioXcel...
BioCentury | Jul 17, 2018
Distillery Therapeutics

Cancer

...cells in peripheral blood and weight loss. Next steps include identifying additional dual DPP-8/DPP-9 inhibitors. BioXcel...
BioCentury | Jul 13, 2018
Finance

Pause for politics

...NASDAQ:FIXX) 3/27/18 $165.6 $598.9 $814.8 36% Arcus Biosciences Inc. (NYSE:RCUS) 3/14/18 $138.0 $656.3 $543.2 -17% BioXcel...
BioCentury | Mar 16, 2018
Financial News

AI play BioXcel raises $60M IPO

...Artificial intelligence company BioXcel Therapeutics Inc. (NASDAQ:BTAI) raised $60 million on March 8 through the sale...
...by Barclays, UBS, BMO and Canaccord Genuity. The price valued the company at $172.1 million. BioXcel...
...both programs into Phase II proof-of-concept studies this year. BioXcel Therapeutics Inc. (NASDAQ:BTAI), Branford, Conn. Sandi Wong BioXcel...
BioCentury | Mar 8, 2018
Financial News

AI play BioXcel raises $60M IPO

...by Barclays, UBS, BMO and Canaccord Genuity. The price valued the company at $172.1 million. BioXcel...
...AI to identify new indications for approved or clinically validated products. An IV formulation of BioXcel's...
...cancer. The biotech plans to move both programs into Phase II proof-of-concept studies this year. Sandi Wong BXCL501 BXCL701 BioXcel...
BioCentury | Feb 23, 2018
Financial News

BioXcel Therapeutics proposes $69M IPO

...Artificial intelligence company BioXcel Therapeutics Inc. (Branford, Conn.) proposed on Feb. 13 to raise up to...
...Genuity. BioXcel Therapeutics is a subsidiary of BioXcel Corp. (Branford, Conn.). BioXcel Therapeutics Inc., Branford, Conn. Sandi Wong BioXcel Corp. BioXcel...
Items per page:
1 - 10 of 15
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

...SVP of chemistry and biology business unit at Shanghai Medicilon Inc. (Shanghai:688202).Neuroscience and immuno-oncology company BioXcel...
...VP of R&D. BC Staff Intercept Blood System for plasma (amotosalen, Intercept Plasma System (S-59)) TScan Therapeutics Insilico Biotechnology Kira Biotech BioXcel Re-Vana...
BioCentury | Jun 26, 2020
Management Tracks

Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst

...Randy Scott to the board. Scott was executive chairman and CEO of Invitae Corp. (NYSE:NVTA). BioXcel...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...OTCQX:RHHBY), where she was global head of the pharma’s neuromuscular franchise. Neuroscience and immuno-oncology play BioXcel...
...VP of clinical development at Merus N.V. (NASDAQ:MRUS). Robin Sawka, BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise Therapeutics BioXcel...
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...Inc. Dewpoint Therapeutics FerGene Inc. Adverum Biotechnologies Inc. Epsilen Bio s.r.l. Kaleido Biosciences Inc. Laboratory for Advanced Medicine Inc. Mundipharma International Ltd. MacroGenics Inc. BioXcel...
BioCentury | Jan 18, 2019
Financial News

Gore Range closes its inaugural fund

...Fund I raised. Fund I has made 13 investments, including in neuroscience and immuno-oncology company BioXcel...
...dermatology, cancer and cardiovascular biotechs and innovative technology companies. Gore Range Capital, New York, N.Y. Jennie Walters BioXcel...
BioCentury | Jul 17, 2018
Distillery Therapeutics

Cancer

...cells in peripheral blood and weight loss. Next steps include identifying additional dual DPP-8/DPP-9 inhibitors. BioXcel...
BioCentury | Jul 13, 2018
Finance

Pause for politics

...NASDAQ:FIXX) 3/27/18 $165.6 $598.9 $814.8 36% Arcus Biosciences Inc. (NYSE:RCUS) 3/14/18 $138.0 $656.3 $543.2 -17% BioXcel...
BioCentury | Mar 16, 2018
Financial News

AI play BioXcel raises $60M IPO

...Artificial intelligence company BioXcel Therapeutics Inc. (NASDAQ:BTAI) raised $60 million on March 8 through the sale...
...by Barclays, UBS, BMO and Canaccord Genuity. The price valued the company at $172.1 million. BioXcel...
...both programs into Phase II proof-of-concept studies this year. BioXcel Therapeutics Inc. (NASDAQ:BTAI), Branford, Conn. Sandi Wong BioXcel...
BioCentury | Mar 8, 2018
Financial News

AI play BioXcel raises $60M IPO

...by Barclays, UBS, BMO and Canaccord Genuity. The price valued the company at $172.1 million. BioXcel...
...AI to identify new indications for approved or clinically validated products. An IV formulation of BioXcel's...
...cancer. The biotech plans to move both programs into Phase II proof-of-concept studies this year. Sandi Wong BXCL501 BXCL701 BioXcel...
BioCentury | Feb 23, 2018
Financial News

BioXcel Therapeutics proposes $69M IPO

...Artificial intelligence company BioXcel Therapeutics Inc. (Branford, Conn.) proposed on Feb. 13 to raise up to...
...Genuity. BioXcel Therapeutics is a subsidiary of BioXcel Corp. (Branford, Conn.). BioXcel Therapeutics Inc., Branford, Conn. Sandi Wong BioXcel Corp. BioXcel...
Items per page:
1 - 10 of 15